Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


In an organic compound

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424100110 - RADIONUCLIDE OR INTENDED RADIONUCLIDE CONTAINING; ADJUVANT OR CARRIER COMPOSITIONS; INTERMEDIATE OR PREPARATORY COMPOSITIONS

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
424100810 Nonmetal radionuclide or intended radionuclide (e.g., carbon) 267
424100690 Attached to peptide or protein of 2+ amino acid units (e.g., dipeptide, folate, fibrinogen, transferrin, sp. enzymes); derivative thereof 260
424100730 Attached to carbohydrate compound; derivative thereof (e.g., DNA, nucleotide, nucleoside, sugar, starch, tannin, saccharide, polysaccharide, cellulose, O-, N- and S-glycoside, vitamin B12) 59
424100770 Phosphorus-containing organic compound 21
Entries
DocumentTitleDate
20110182810CENTRAL NERVOUS SYSTEM LABELLING COMPOSITION FOR INTRANASAL ADMINISTRATION AND LABELLING METHOD AND SCREENING METHOD USING CENTRAL NERVOUS SYSTEM LABELLING COMPOSITION FOR INTRANASAL ADMINISTRATION - There is provided a central nervous system labelling composition for intranasal administration for the purpose of labelling the central nervous system from the olfactory epithelium by way of the olfactory bulb and by means of intranasal administration. Additionally, there is provided a method of non-invasively labelling the central nervous system by way of an administration route that entails little transferability to the entire body. Furthermore, there is provided a screening method using a central nervous system labelling composition for intranasal administration. A central nervous system labelling composition for intranasal administration is characterized by labelling the central nervous system from the olfactory epithelium by way of the olfactory bulb and by means of intranasal administration and by containing at least one compound expressed either by the general formula (1) or the general formula (2) shown below as effective component:07-28-2011
20100150831MODULATORS OF CXCR7 - Compounds having formula I,06-17-2010
20100015049METHODS AND COMPOSITIONS FOR TREATING POSTOPERATIVE PAIN COMPRISING NONSTEROIDAL ANTI-INFLAMMATORY AGENTS - Methods and compositions are provided for reducing, treating or preventing postoperative pain and/or inflammation in a patient in need of such treatment, the methods and compositions comprising administering one or more biodegradable drug depots comprising a therapeutically effective amount of diclofenac and/or ketoprofen or pharmaceutically acceptable salt thereof to a target tissue site, wherein the drug depot releases an effective amount of diclofenac and/or ketoprofen or pharmaceutically acceptable salt thereof over a period of 3 to 15 days.01-21-2010
20100143248METHODS FOR DIAGNOSING AND MONITORING TREATMENT OF ADHD BY ASSESSING THE DOPAMINE TRANSPORTER LEVEL - A method of diagnosing attention deficient-hyperactivity disorder (ADHD) in a human patient by assessing the level of dopamine transporter in at least one region of the patient's central nervous system, where an elevated level of dopamine transporter in the patient is indicative of ADHD. In embodiments of the invention, assessment of dopamine transporter levels includes assessing binding of a dopamine transporter ligand to the dopamine transporters using PET or SPECT.06-10-2010
20100074842Technetium-99m (I) Tricarbonyl Complexes with Tridentate Chelators for Myocardium Imaging - Chelators of the formulae (I), (II) and (III) and tricarbonyl complexes of radioisotopes of Tc and Re bound to them, for use in myocardial imaging.03-25-2010
20130034494RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS - Compounds according to Formula I and Formula II are potent inhibitors of PSMA activity:02-07-2013
20090324494MAGNETIC NANO-COMPOSITE FOR CONTRAST AGENT, INTELLIGENT CONTRAST AGENT, DRUG DELIVERY AGENT FOR SIMULTANEOUS DIAGNOSIS AND TREATMENT, AND SEPARATION AGENT FOR TARGET SUBSTANCE - The present invention relates to water soluble magnetic nanocomposite using an amphiphilic compound. Specifically, the present invention relates to water soluble magnetic nanocomposite which may be not only used as a contrast agent for magnetic resonance imaging (MRI), an intelligent contrast agent for diagnosing cancer characterized by binding a tissue-specific binder ingredient, a drug delivery system for simultaneous diagnosis and treatment by polymerizing or enveloping drugs and binding a tissue-specific binder ingredient, but also used for separating a target substance using magnetism, and a process for preparing the same.12-31-2009
20100104512Dendritic Chelated Compounds, Methods for Making the Same and Pharmaceutical Compositions Containing the Same - The invention relates to dendritic chelated compounds, to methods for producing the same and to pharmaceutical compositions containing the same. The dendritic chelated complexes of the present invention have the following formula (I): [[MC]E04-29-2010
20090155168IN VIVO IMAGING COMPOUNDS - The invention relates to a compound of formula (I) having use for in vivo imaging of the NR2B subtype of the NMDA receptor.06-18-2009
20120164070BENZOTHIAZOLE AND BENZOOXAZOLE DERIVATIVES AND METHODS OF USE - Compounds of formula (I)06-28-2012
20090304584CONJUGATES COMPRISING A GABA- OR GLYCINE COMPOUND, PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS THEREOF AND THEIR USE IN TREATING CNS DISORDERS - Conjugates of a gamma-aminobutyric acid (GABA) compound or a glycine compound and an analgesic drug are disclosed. Further disclosed are pharmaceutical compositions containing these conjugates and uses thereof in the treatment of CNS-associated diseases or disorders, optionally in combination with a psychotropic drug.12-10-2009
20090304583PATHOLOGICAL TISSUE DETECTION AND TREATMENT EMPLOYING TARGETED BENZOINDOLE OPTICAL AGENTS - Novel tumor specific phototherapeutic and photodiagnostic agents are disclosed. The compounds consist of a carbocyanine dye for visualization, photosensitizer for photodynamic treatment, and tumor receptor-avid peptide for site-specific delivery of the probe and phototoxic agent to diseased tissues. A combination of these elements takes full advantage of the unique and efficient properties of each component for an effective patient care management.12-10-2009
20090092547Injectable Particles - According to an aspect of the invention, injectable polymeric particles are provided which contain branched poly(vinyl alcohol). Other aspects of the invention pertain to methods of making such particles. Still other aspects of the invention pertain to injectable compositions that comprise such particles and to methods of treatment that employ such injectable compositions.04-09-2009
20110014121MODULATORS OF CXCR7 - Compounds having formula I,01-20-2011
20120225015Method for predicting autism spectrum disorders by cannabinoid and cannabinoid receptor expression - The inventive method relates to a method for the determination of susceptibility or diagnosis of autism or autism spectrum disorders. Diagnosis or determination of susceptibility determinations are predicated on quantitative analysis of endocannibinoid levels or endocannibinoid receptor expression.09-06-2012
20130064764Miniaturized 62Zn/62Cu Generator for High Concentration Clinical Delivery of 62Cu Kit Formulation for the Facile Preparation of Radiolabeled Cu-BIS(Thiosemicarbazone) Compounds - A new system accomplishes easy, interchangeable production of multiple PET radiopharmaceuticals through the use of a simplified eluant-only generator and a kit based synthesis technique employing lyophilized or freeze dried ligand. Thus, by simply switching the lyophilized ligand vial kit, any number of 03-14-2013
20090238758RANDOM AND NON-RANDOM ALKYLENE OXIDE POLYMER ALLOY COMPOSITIONS - A polymeric material comprised of (i) at least one random copolymer comprised of ethylene oxide and one or more other alkylene oxide(s) and (ii) at least one non-random polymer comprised of one or more poly(alkylene oxide)s has been discovered. Preferably, it is a polymer alloy. Alkylene oxide homopolymers or block copolymers may be the non-random polymer. In a related discovery, an adhesive material can be made by suspending (a) particles in (b) a matrix of at least one poly(ethylene oxide) copolymer of ethylene oxide and propylene oxide, or a combination thereof. The handling characteristics may be adjusted for different utilities (e.g., from runny oil to hard wax). Applications include use as adhesive, cohesive, filler, lubricant, surfactant, or any combination thereof. In particular, the hard materials may be used for cleaning or waxing.09-24-2009
20090238756IMAGE-GUIDED THERAPY OF MYOCARDIAL DISEASE: COMPOSITION, MANUFACTURING AND APPLICATIONS - Compositions and methods for imaging and for chemotherapy and radiotherapy are disclosed. More particularly, the invention concerns agents comprising a targeting moeity comprising a beta-adrenergic receptor targeting compound conjugated or embedded with ethylenediamine. The present invention also concerns methods of application of such agents for imaging and treatment of cardiovascular diseases, and kits for preparing a radiolabeled therapeutic or diagnostic agent.09-24-2009
20100003190Method for protecting renal tubular epithelial cells from radiocontrast nephropathy (RCN) - According to aspects of the invention, methods for preventing or treating kidney damage are provided. Compositions for the prevention or treatment of kidney damage are also provided. Aspects of the invention relate to methods for screening the toxicity of a radio-contrast agent. Kits for the treatment or prevention of kidney damage are also provided.01-07-2010
20090104116COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF - The present invention is related to a compound of formula (I), wherein A is a nonaromatic heterocyclic ring, Ar is either absent or phenylene; Ψ is a radical of formula (II), R04-23-2009
20090202435Diagnostic compounds for targeting a chemokine receptors - The present invention relates to a compound comprising, firstly a component for targeting at least one chemokine receptor and, secondly, a detection component capable of being identified by a medical imaging method.08-13-2009
20110293515HETEROFUNCTIONAL SEGMENT-POLY (ETHYLENE GLYCOL) POLYMERS AS DELIVERY VEHICLES - Heterofunctional segment-poly(ethylene glycol) polymers, conjugates of these molecules with therapeutic and/or imaging agents, and methods for their use are disclosed. The heterofunctional segment-poly(ethylene glycol) polymers are useful as drug delivery conjugates, i.e., the heterofunctional segment-poly(ethylene glycol) polymers can be covalently attached to therapeutic agents (e.g., pharmaceutically active agents) and serve as delivery vehicles for the therapeutic agents. The heterofunctional segment-poly(ethylene glycol) polymers are also useful as imaging agent conjugates, i.e. the heterofunctional segment-poly(ethylene glycol) polymers can be covalently attached to imaging agents (e.g., tracers, imaging atoms, and imaging molecules) and serve as delivery vehicles for the imaging agents. Also disclosed are methods for treating a subject by administering to the subject an effective amount of the polymers conjugated to a therapeutic agent, an imaging agent, or a mixture thereof.12-01-2011
20100189644ARGINASE INHIBITORS AND METHODS OF USE - The present invention is directed to arginase inhibitor compounds of formula IA or formula IB:07-29-2010
20100098631Novel-2-Heteroaryl Substituted Indoles 695 - The present invention relates to novel 2-heteroaryl substituted indole derivatives, precursors thereof, and therapeutic uses of such compounds, having the structural formula (Ia) below: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel 2-heteroaryl substituted indole derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer?s disease therapeutic agents.04-22-2010
20110262352ARYL PIPERAZINE AND THEIR USE AS ALPHA2C ANTAGONISTS - Compounds of formula (I), wherein X, Z, A, B, D, E, R10-27-2011
20100111858Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands - The present invention provides conjugates useful for the diagnosis and treatment of diseases associated with the over-expression of COX-2. The conjugates comprise a selective COX-2 targeting carrier, a metal coordinating moiety, and a linker chemically linking the metal coordinating moiety to the carrier. The metals coordinated by the metal coordinating moiety are selected from paramagnetic or radioisotopes. The invention also includes kits comprising a conjugate and a radioisotope solution.05-06-2010
20100111859Visualization of Biological Material by the Use of Coated Contrast Agents - A method for visualizing biological material, preferably by MRI, comprising the steps of: (i) bringing a population of coated nanoparticles into contact with said biological material, each of which nanoparticles comprises a) a metal oxide of a transition metal, said metal oxide preferably being paramagnetic and preferably comprising a lanthanide (+III) such as gadolinium (+III), and b) a coating covering the surface of the core particle, and (ii) recording the image; wherein the coating is hydrophilic and comprises a silane layer which is located next to the surface of the core particle and comprises one or more different silane groups which each comprises an organic group R and a silane-siloxane linkage where a) R comprises a hydrophilic organic group R′ and a hydrophobic spacer B, b) O is oxygen directly binding to a surface metal ion of the metal oxide, and c) C is carbon and is also part of B. A composition for visualization and methods for the manufacture of the nanoparticles and core particles are also disclosed. Visualization includes imaging by MR, CT, X-ray, near IR fluorescence, PET, microscopying etc with the largest advantages accomplished for in-vivo imaging.05-06-2010
20120189543Compositions and Methods for Detecting and Treating Implant Loosening and Osteolysis - Methods and compositions for detecting, diagnosing, and treating osteolysis and implant loosening are disclosed.07-26-2012
20090087377COMPOSITIONS FOR TARGETED IMAGING AND THERAPY - The present invention relates to the field of radiochemistry, nuclear imaging, radionuclide therapy and chemical synthesis. More particularly, it concerns a strategy for radiolabeling target ligands. It further concerns methods of using those radiolabeled ligands for imaging, radionuclide therapy and tissue-specific disease imaging.04-02-2009
20090081123PHARMACEUTICAL COMPOUNDS - Tricyclic pyrazole derivatives of the following formula (I) having affinity for the cannabinoidergic CB1 and/or CB2 receptors:03-26-2009
20090252674Tripodal Ligands with the Coordinating Motifs K2 -BH2 or K3 -BH3 Relevant for Biomedical Applications of Organometallic Complexes - The present invention relates to a compound for use as a chelator in the radioactive labeling of biomolecules with metal tricarbonyl complexes, which compound has the general Formula (I) wherein M is a monovalent cation, such as Li, Na, K, Tl, Rb, Cs or an alkyl ammonium; R1 is H, alkyl, aryl or a biomolecule; R2 is H or a pendant arm, said pendant arm optionally comprises a biomolecule, with the proviso that when R1 is H, R2 is not H or COOH, and when R1 is alkyl or aryl, R2 is not H.10-08-2009
20120269724COMPOSITIONS AND METHODS FOR IMAGING TISSUES, ORGANS AND TUMORS - The present invention relates to compounds and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled metal complexes, particularly tissues, organs, or tumors which express certain receptors to which the compounds or complexes of the invention have an affinity. The present invention also relates to methods of treating cancer, particularly those cancer lines which express certain receptors to which the compounds or complexes of the invention have an affinity. In yet another embodiment, the present invention provides methods of imaging and/or inhibiting receptors or neuroreceptors using compounds or complexes of the invention which have an affinity for the receptor or neuroreceptor to be imaged and/or inhibited.10-25-2012
20100098630Phenazine and Quinoxaline Substituted Amino Acids and Polypeptides - Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a phenazine or quinoxaline substituent. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides.04-22-2010
20100098629Novel Amides Acting on the Adenosine Receptors - There are described Compounds of formula (I) in which R04-22-2010
20120107236LIVER- RECEPTOR IMAGING INJECTION, DISPENSING METHOD AND PHARMACEUTICAL COMPOSITION THEREOF - The present invention is related to a pharmaceutical composition for a liver-receptor imaging injection, the pharmaceutical composition including a bi-functional compound which has a ASGPR specificity, wherein the bi-functional compound includes a backbone of alpha-amino acid (or the derivatives thereof) and a poly-galactosamine chain (or a poly-lactose chain) connected to the alpha-amino acid. Thereby, the pharmaceutical composition can quantify potential of liver storage ability and evaluate severity of the course of liver disease. A liver-receptor imaging injection using the same and the one-step dispensing method thereof are also provided to improve defects of iodine-labeled and overcome disadvantages of the reduced labeling-yield and the instability after autoclave sterilization.05-03-2012
20080206135Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid - The present invention relates to novel modified fatty acid analogs, where a positron or gamma-emitting label is placed at a position on a fatty acid backbone and an organic substituent is substituted at the 2,3; 3,4; 4,5; 5,6 and other sequence positions of a fatty acid backbone. These novel fatty acid analogs are designed to enter the tissues of interest by the same long chain fatty acid carrier mechanism as natural fatty acids, however, functional substituents in the 2,3; 3,4; 4,5; 5,6 and other sequence positions, block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest.08-28-2008
20090274621USE OF PYRENE TO CARRY NON-PEPTIDE AGENTS ACROSS THE BLOOD BRAIN BARRIER - Described are methods for delivering a non-peptide agent across the blood-brain barrier, comprising administering to a subject a conjugate comprising (i) a non-peptide agent and (ii) pyrene, and related detection and therapeutic method.11-05-2009
20080213173Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid - The present invention relates to novel modified fatty acid analogs, where a positron or gamma-emitting label is placed at a position on a fatty acid backbone and an organic substituent is substituted at the 2,3; 3,4; 4,5; 5,6 and other sequence positions of a fatty acid backbone. These novel fatty acid analogs are designed to enter the tissues of interest by the same long chain fatty acid carrier mechanism as natural fatty acids, however, functional substituents in the 2,3; 3,4; 4,5; 5,6 and other sequence positions, block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest.09-04-2008
20100290986THERAPEUTIC USE OF DIAMINOPHENOTHIAZINES - The present invention relates generally to methods and materials for use in the treatment or prophylaxis of diseases, for example cognitive disorders, using diaminophenothiazines. In particular it relates to treatments having optimised pharmacokinetic properties, and dosage forms are intended to improve the relative cognitive or CNS benefits of the diaminophenothiazines, for instance compared to haematological effects.11-18-2010
20100143249FOLATE-CONJUGATES AND CORRESPONDING METAL-CHELATE COMPLEXES FOR USE IN DIAGNOSTIC IMAGING AND RADIOTHERAPY - The present invention is directed towards novel folate-conjugates of formula I06-10-2010
20090169472METHODS AND COMPOSITIONS FOR TREATING IMMUNE DISORDERS - The present invention provides oligonucleotides, compositions comprising them and methods that use the oligonucleotides and compositions for stimulating cells expressing the TLR7 and/or TLR8 receptor. The oligonucleotides comprise for stimulating TLR7 comprise uracil-rich regions. The oligonucleotides for stimulating TLR8 comprise guanine-rich regions. The present methods and compositions are useful, inter alia, for treating or preventing conditions such as infectious disease and cancer.07-02-2009
20080233047Symmetric and Asymmetric Halogen-Containing Metallocarboranylporphyrins and Uses Thereof - The present invention is directed to low toxicity boronated compounds and methods for their use in the treatment, visualization, and diagnosis of tumors. More specifically, the present invention is directed to low toxicity halogenated, carborane-containing 5,10,15,20-tetraphenylporphyrin compounds and methods for their use particularly in boron neutron capture therapy (BNCT) and photodynamic therapy (PDT) for the treatment of tumors of the brain, head and neck, and surrounding tissue. The invention is also directed to using these halogenated, carborane-containing tetraphenylporphyrin compounds in methods of tumor imaging and/or diagnosis such as MRI, SPECT, or PET.09-25-2008
20080305039Facilitated Transport of Bisphosphonates by Vitamin C - Compounds of the formula: are described wherein: A12-11-2008
20080305040In Vivo or in Vitro Method For Detecting Amyloid Deposits Having at Least One Amyloidogenic Protein - An amyloid deposit can be detected by administering to a subject or applying to a sample a compound of Formula (I) or Formula (II) or structures 1-45, as described, and then imaging to detect binding of the compound to an amyloid deposit, where the amyloido genie protein of the deposit can be AL, AH, ATTR, Aβ2M, AA, AApoAI, AApoAII, AGeI, ALys, AFib, ACys, ABri, ADan, APrP, ACaI, AlAPP, AANF, APro, AIns, AMed, AKer, A(tbn), and/or ALac.12-11-2008
200903111762-Arylpyrazolo[L,5-Alpha] Pyrimidin-3-YL Acetamide Derivatives as Ligands for Translocator Protein (18 Kda) - The invention provides compounds of formula (I) radiolabelled with 12-17-2009
20110206604NITROIMIDAZOLE-AMINO ACID HYPOXIA CONTRAST MEDIUM, PREPARATION METHOD AND USE THEREOF - A hypoxia contrast medium including nitroimidazole-amino acid chelate with a positively charged radioactive nuclide, a preparation method and use thereof. The contrast medium can be used in imaging cerebral thrombosis, tumors or other diseases such as ulceration, thrombosis, and so on.08-25-2011
20080279769Enzyme Inhibitor Imaging Agents - The present invention discloses that imaging agents which comprise a specific type of matrix metalloproteinase inhibitors (MMPi's) of the hydroxamate class labelled with an imaging moiety, are useful diagnostic imaging agents for in vivo imaging and diagnosis of the mammalian body.11-13-2008
20090123369Styrylpyridine Derivatives and Their Use for Binding and Imaging Amyloid Plaques - This invention relates to a method of imaging amyloid deposits and to styrylpyridine compounds, and methods of making radiolabeled styrylpyridine compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.05-14-2009
20090087376Heterocyclic Dye Compounds For In Vivo Imaging And Diagnosis Of Alzheimer's Disease - The present invention relates to the identification of compounds that are suitable for imaging amyloid deposits in living patients. The invention relates, in part, to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease. The present invention also relates to therapeutic uses for such compounds, as exemplified by compounds of the formula (1) in which Y is independently S, O, or N and m is 1, 2, or 3.04-02-2009
20090180951INHIBITORS OF INTEGRIN VLA-4 - A complex, its stereoisomer or pharmaceutically acceptable salt has the formula I, where:07-16-2009
20090162280DETECTING SOLUBLE A-BETA - Agents, methods, and kits for qualitatively or quantitatively determining the presence of soluble A-beta in source of A-beta are provided, wherein the agents comprise the compound of formula III or the compound of formula III labeled with a signal generator.06-25-2009
20090136419HIGH DOSE RADIONUCLIDE COMPLEXES FOR BONE MARROW TREATMENT - The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.05-28-2009
20090220418MULTIMODAL IMAGING USING A THREE COMPARTMENT POLYMER NANOPARTICLE WITH CELL SPECIFICITY - The present invention pertains to a three compartment structured polymer nanoparticle (core-shell-corona) for multimodal imaging with specificity for cells or cellular components, thus enabling more advanced diagnostic approaches and targeted therapy on the cellular level without the use of additional biologically active materials.09-03-2009
20090252676N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS - The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.10-08-2009
20090252677Probes for In Vivo Targeting of Active Cysteine Proteases - Activity-based probes, which are specific for certain active cysteine proteases (caspase, cathepsin and legumain) and carry radioactive labels, are disclosed. The present probes comprise an acyloxymethyketone (AOMK) “warhead” that binds only to active enzyme. The probes further comprise peptide-like structure that targets the probe to a specific cysteine protease or protease family, and a radiolabel on the probe, which is bound to the targeted enzyme. It has been found that the present probes are stable in vivo and give specific target images distinguishable over background. The preferred probes are labeled with a positron-emitting agent such as 10-08-2009
20100003191AURONE DERIVATIVE-CONTAINING COMPOSITION FOR DIAGNOSIS - The present invention provides a composition for diagnosing amyloid-related diseases, comprising a compound represented by general formula (I):01-07-2010
20120195832PROCESS FOR PRODUCING AN INJECTABLE MEDICAMENT PREPARATION - The invention relates to a method for producing injectable medicament preparations containing a therapeutically and/or diagnostically effective substance which is comprised of an active agent, of a spacer molecule and of at least one protein-binding molecule. After being brought into contact with the body, said therapeutically and/or diagnostically effective substance covalently bonds to the body fluid constituents or tissue constituents via the protein-binding molecule, thus providing a form of transport of the active agent that an be hydrolytically or enzymatically cleaved, according to pH, in the body while releasing the active agent.08-02-2012
20100178246TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA - A compound of Formula I, a pharmaceutically acceptable salt, or solvate thereof:07-15-2010
20100178247CA-IX SPECIFIC RADIOPHARMACEUTICALS FOR THE TREATMENT AND IMAGING OF CANCER - A compound that recognizes and binds to the CA-IX protein has Formula I, II, III, or IV. The compounds may include a radioactive element for radioimaging or therapeutic applications. Thus, pharmaceutical compositions may be prepared with one or more of the compounds of Formula I, II, III, or IV.07-15-2010
20100150832BIODEGRADABLE POLYKETAL POLYMERS AND METHODS FOR THEIR FORMATION AND USE - The present invention relates to biodegradable biocompatible polyketals, methods for their preparation, and methods for treating animals by administration of biodegradable biocompatible polyketals. In one aspect, a method for forming the biodegradable biocompatible polyketals comprises combining a glycol-specific oxidizing agent with a polysaccharide to form an aldehyde intermediate, which is combined with a reducing agent to form the biodegradable biocompatible polyketal. The resultant biodegradable biocompatible polyketals can be chemically modified to incorporate additional hydrophilic moieties. A method for treating animals includes the administration of the biodegradable biocompatible polyketal in which biologically active compounds or diagnostic labels can be disposed. The present invention also relates to chiral polyketals, methods for their preparation, and methods for use in chromatographic applications, specifically in chiral separations. A method for forming the chiral polyketals comprises combining a glycol-specific oxidizing agent with a polysaccharide to form an aldehyde intermediate, which is combined with a suitable reagent to form the chiral polyketal. A method for use in chiral separations includes the incorporation of the chiral polyketals in the mobile phase during a chromatographic separation, or into chiral stationary phases such as gels. The present invention further relates to chiral polyketals as a source for chiral compounds, and methods for generating such chiral compounds.06-17-2010
20100183509TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF - Complexes of heterocyclic radionuclides are prepared based upon ligands having substituted pyridyl and imidazolyl groups. The ligands are bifunctional, having amino acid residues that may act as a linker to a bioactive molecule, and a tridentate chelator that may complex the radionuclide. The bioactive molecule may be a peptide or somatostatin.07-22-2010
20100260671COMPOUNDS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AMYLOID ASSOCIATED DISEASES - The invention is in general directed to compounds, such as tannic acid, nicotine, nicotine derivatives and pyrrolid derivatives of nicotine, and methods for diagnosing, preventing or alleviating the symptoms of amyloid-associated diseases, for example, neuronal diseases, such as, for example, Alzheimer's disease, compounds and methods for inhibiting ion channel activity of beta amyloid, and methods of diagnostic imaging of A/3 fibrils.10-14-2010
20090117040Novel pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases - The present invention relates to pharmaceutical and diagnostic compositions as well as to the use of the active substances contained therein for preparing a pharmaceutical or a diagnostic composition for the treatment or diagnosis of neurodegenerative disorders or amyloid diseases.05-07-2009
20100183508RADIOACTIVE MIXTURE AND MANUFACTURING METHOD THEREOF - A radioactive mixture and a manufacturing method thereof are disclosed. The radioactive mixture (07-22-2010
20100189643DRUG DELIVERY WITH STIMULUS RESPONSIVE BIOPOLYMERS - The present invention provides conjugate compounds comprising (a) an active compound; (b) optionally, but in some embodiments preferably, an affinity binding agent; and (c) a block copolymer, the block copolymer comprising: (i) a first elastin-like polypeptide having a first Tt and (U) a second elastin-like polypeptide having a second Tt greater than the first Tt. Method for the targeted delivering of an active compound in vivo to a selected region within a subject with such agents are also described.07-29-2010
20100150833COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES - The present invention provides compounds and amyloid probes thereof that allow for an antemortem method of diagnosing AD and quantitating the extent or progression of amyloid deposits (plaques) by in vivo imaging of amyloid and/or amyloid deposits in the regions of the brain. Preferably, an amyloid probe of the invention can cross the blood-brain barrier and distinguish AD brain from normal brain. An amyloid probe can be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits. Amyloid probes of the invention can also be used to detect and quantitate amyloid deposits in diseases including, without limitation, Down's syndrome, familial AD and homozygotes for the apolipoprotein E4 allele. In one aspect, the compounds may be used in the treatment or prophylaxis of diseases that include, without limitation, AD and type 2 diabetes mellitus. The compounds and amyloid probes of the invention include analogs, salts, pharmaceutical compositions, derivatives, prodrugs, racemic mixtures or tautomeric forms thereof.06-17-2010
20130216477METAL COMPLEXES OF POLY(CARBOXYL)AMINE-CONTAINING LIGANDS HAVING AN AFFINITY FOR CARBONIC ANHYDRASE IX - The present invention is directed to CA IX inhibitors that conform to Formula I where the substituents X, A, B, D, E, E′ and G are as defined above.08-22-2013
20130216478Non-Invasive Diagnostic Agents of Cancer and Methods of Diagnosing Cancer, Especially Leukemia and Lymphoma - The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.08-22-2013
20100239496Imaging agents for detecting neurological disorders - Imaging agents of formula (I) and methods for detecting neurological disorders comprising administering to a patient in need compounds of formula (I) capable of binding to tau proteins and β-amyloid peptides are presented herein. The invention also relates to methods of imaging Aβ and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formula (I) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disorders.09-23-2010
20100254900Biocompatible polymers and Methods of use - Compositions and methods for manufacturing polymers are disclosed. Compositions include novel plastics, including films and shaped forms comprising polymer matrices that are biologically compatible and biodegradable. Such plastics may comprise polymers derived from natural sources. Further, such plastics are useful in biological systems for wound repair, implants, stents, drug encapsulation and delivery, and other applications. The disclosed methods comprise mild manufacturing processes such that various additives, such as biologically active proteins, sugars, lipids, and the like may be incorporated into the polymer matrix without subsequent loss of bioactivity during processing. Additionally, methods of manufacture for controlling mechanical properties, such as elasticity, pliancy, and the porosity of such plastics are disclosed.10-07-2010
20090252675Radionuclide Therapy for Urinary Bladder Cancer - The compounds used in this method for the treatment of bladder cancer comprise a radioisotope particle emitter, such as alpha- or beta-emitters or low energy gamma-emitters, associated with a chelating agent (for metallic radioisotopes) or other compound (by covalent bond for iodine or other non-metals) selected such that these permit delivery of the radionuclide by an I.V. injection that is then cleared into the bladder by the kidneys. Furthermore, it is expected that these radioisotopes are formulated with customary pharmaceutically-acceptable salts, adjuvants, binders, desiccants, diluents, and excipients.10-08-2009
20100196269SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE - Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ-opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ-opioid receptor-mediated diseases, disorders, and/or conditions.08-05-2010
20080292547Novel Imaging Agents for Fibrosis - The present invention provides a novel imaging agent suitable for the non-invasive visualization of fibrosis. A method for the preparation of the imaging agent is also provided by the invention, as well as a precursor for use in said method. Also provided is a pharmaceutical composition comprising the imaging agent and a kit for the preparation of the pharmaceutical. In a further aspect, use of the imaging agent for in vivo imaging and in the preparation of a medicament for the diagnosis of a condition in which LOX is upregulated is provided.11-27-2008
20110033379RADIO-LABELED MATERIALS AND METHODS OF MAKING AND USING THE SAME - Radio-labeled materials, e.g., compounds and compositions, methods of making the radio-labeled materials, and applications of the same are disclosed. For example, novel solid-state methods are disclosed that produce radio-labeled compositions that include a reactive, but stable radio-labeled compound in a polar anhydrous solvent. The radio-labeled compounds can be readily conjugated with a variety of ligands.02-10-2011
20110117015Diagnostic Agents Selective Against Metalloproteases - The invention relates to aryl-sulphonamido compounds endowed with affinity against metallo proteases MMP, having formula (I) below wherein R, R05-19-2011
20110117014NON-INVASIVE DIAGNOSTIC AGENTS AND METHODS OF DIAGNOSING INFECTIOUS DISEASE - The present invention is directed to novel non-invasive diagnostic tools to diagnose numerous infectious disease states or conditions. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these disease states. The novel imaging probe is capable of detecting infected cells, as well tissue. This represents a quanturn step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to therapeutic treatments and other interventions or therapies used in the treatment of these disease states or conditions. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states. Pharmaceutical compositions are also described.05-19-2011
20110243844SULFONAMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS - Disclosed are mGluR4 positive allosteric modulator ligands of general formula (I) and radiolabeled derivates, their use as therapeutic agents for the treatment of central nervous system disorders modulated by mGluR4 and as ligands for the labeling and diagnostic imaging of mGluR4 in mammals.10-06-2011
20110243843FLUORESCENT SILICA NANOPARTICLES FOR DETECTING LYMPH NODE AND THE IDENTIFICATION METHOD OF LYMPH NODE USING THEREOF - The present invention relates to fluorescent silica nanoparticles for detecting lymph node and identification method of lymph node using thereof. The functionalized silica nanoparticles containing fluorescent dye of this invention have a promising potential for sentinel node detection in the surgical field through fluorescent imaging.10-06-2011
20110135571HYBRID NANOPARTICLES AS ANTI-CANCER THERAPEUTIC AGENTS AND DUAL THERAPEUTIC/IMAGING CONTRAST AGENTS - The presently disclosed subject matter provides nanoscale coordination polymers for use as anticancer agents and as dual anticancer/imaging agents. The nanoscale coordination polymers can comprise a plurality of platinum metal complexes; nonplatinum anticancer drug bridging ligands complexed to multiple metal centers; or combinations thereof. The nanoscale coordination polymers can be targeted for delivery to cancer cells. They can also comprise stabilizing agents to allow for controlled and/or sustained release of anticancer agents in vivo.06-09-2011
20100015050PEG AND TARGETING LIGANDS ON NANOPARTICLE SURFACE - Provided are compositions of nanoparticles, PEG and targeting moieties. The compositions are useful in treating tumors, imaging the particles in tissues, and in targeting therapeutic agents to specific tissues and locations in a patient. Also provided are methods of preparing and methods of using the compositions.01-21-2010
20100068138STRUCTURALLY RIGID DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND PROCESS FOR MAKING THEM - A family of structurally rigid dopamine D3 receptor selective ligands is described. The family of structurally rigid dopamine D3 receptor selective ligands has the formula wherein A is cis or trans —CH═CH—, —C═C—, or cyclohexyl. B is cis or trans —CH═CH— or absent. R1 represents an optionally substituted phenyl group, wherein said substituents are selected from the group consisting of: hydrogen, halogen, amino, nitro, hydroxyl, alkoxy, alkyl, acyl and pyridyl, and said substitution may occur at any of the ortho, meta, or para positions, or R1 represents a heteroaromatic ring. A preferred heteroaromatic ring is indole, quinoxoline, pyridyl, pyrimidyl, or imidazole. R2 and R3 may be independently hydrogen or a halogen, or R2 alone may be C1, C2, or C3 alkoxy, and m is 1 or 2, and n is 0, 1, or 2.03-18-2010
20100061928LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS - The present invention relates to the use of a compound of formula (I):03-11-2010
20110104055SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES - Compounds and their pharmaceutically acceptable salts, their synthesis and labeling, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, including Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment are provided. Also provided is the use of the disclosed compounds as imaging agents and methods for in vivo imaging and detection of amyloid and synuclein.05-05-2011
20110250132LIPOIC ACID METABOLITE: USEFUL FOR DRUG CARRIER, NANOPARTICLE CONJUGATE, IMAGING AND HYPERTHERMIA THERAPY - The present invention relates to simultaneous tracking or imaging followed by hyperthermia therapy for cancer and other diseases associated with altered metabolic enzymes. In particular, the invention relates to a novel class of therapeutic nanomaterial which selectively target and kill tumor cells.10-13-2011
20110070157RADIOMETAL-LABELED AMINO ACID ANALOGS, IMAGING AND THERAPEUTIC AGENTS INCORPORATING THE SAME, AND METHODS USING THE SAME - An amino acid analog is provided, in syn-stereoisomeric form, anti-stereoisomeric form, or a combination thereof. The amino acid analog includes a cyclobutane ring with at least one of an amine group and a carboxyl group attached to one carbon node of the cyclobutane ring. A chain of moieties X, Y, and Z attached to one of remaining three carbon nodes of the cyclobutane ring. X is a chelating agent selected from a group comprising DCTA, DOTA, DTPA, EDTA, NOTA, PCTA, and TETA. Y is a linking moiety selected from a group comprising —NH—CO— and —NH-p-CHSN-Bn- where the linking moiety facilitates incorporation of the chelating agent into the amino acid analog. Z is a metal radioisotope selected from a group comprising Cu-60, Cu-61, Cu-62, Cu-64, Cu-67, Ga-67, Ga-68, Y-86, Y-88, Y-90, Sr-85, Sr-89, Gd-153, Gd-157, Sm-153, Lu-177, W-185, Re-186, Re-188, and Ir-192.03-24-2011
20120148491METHOD OF OVERCOMING THERAPEUTIC LIMITATIONS OF NONUNIFORM DISTRIBUTION OF RADIOPHARMACEUTICALS AND CHEMOTHERAPY DRUGS - Disclosed is a method for predicting the optimal amounts of radiopharmaceutical and/or chemotherapy agents to administer to a patient, by determining the level of saturation of the therapeutic agents in the patient's cells. The method comprises measuring cellular incorporation of the candidate therapeutic agents in a target cell population on a cell-by-cell basis. The method is able to identify an optimal cocktail of therapeutic agents for treatment of a disease. A method of high-throughput drug discovery incorporating this method, and a 2-stage targeting method of treating a disease using this method are also disclosed.06-14-2012
20080279770Metal Complexes Based on Tetrathiol Ligands and Their Use in Nuclear Medical Diagnostics and Endoradionuclide Therapy and Method For Producing Said Metal Complexes - The aim of the invention is to provide radiolytically and metabolically stable metal complexes suitable for conjugation with biomolecules and, therefore, useful for nuclear medical diagnostics and in endoradionuclide therapy and to provide a method for their production. This is achieved by metal complexes based on tetrathiol ligands of formula (I), in which (CH—R11-13-2008
20080267866Novel Antiviral Macrocycle Derivatives and Metal Complexes, Incorporating Bridged Macrocycles - A compound of Formulae (1), (2) or (3), A10-30-2008
20110165074CHELATING AMPHIPHILIC POLYMERS - Described are amphiphilic polymers that are provided with chelating moieties. The amphiphilic polymers are block copolymers comprising a hydrophilic block and a hydrophobic block, with the chelating moieties linked to the end-group of the hydrophilic block. The disclosed polymers are capable of self-assembly into structures such as micelles and polymersomes. With suitable metals present in the form of coordination complexes with 5 the chelating moieties, the chelating amphiphilic polymers of the invention are suitable for use in various imaging techniques requiring metal labeling, such as MRI (T 07-07-2011
20090238757Methods and Compositions for Administering Therapeutic and Diagnostic Agents - Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.09-24-2009
20100329978HIGHLY SELECTIVE SIGMA RECEPTOR LIGANDS - Compounds having the general formula II, III, or IV12-30-2010
20110052490ENDOSCOPIC MUCOSAL RESECTIONING USING PURIFIED INVERSE THERMOSENSITIVE POLYMERS - One aspect of the invention relates to use of a composition comprising a purified inverse thermosensitive polymer in an endoscopic procedure for gastrointestinal mucosal resectioning in a mammal. Another aspect of the invention relates to a method of gastrointestinal mucosal resectioning, comprising administering submucosally to a region of a gastrointestinal mucosa in a mammal an effective amount of a composition comprising a purified inverse thermosensitive polymer; and surgically resecting said region of gastrointestinal mucosa. Yet another aspect of the invention relates to a kit for use in gastrointestinal endoscopic mucosal resectioning in a mammal, comprising a composition comprising a purified inverse thermosensitive polymer; a syringe; and instructions for use thereof.03-03-2011
20110085974SMALL MOLECULE LIGAND-DRUG CONJUGATES FOR TARGETED CANCER THERAPY - The present invention describes small molecule ligand-drug conjugates and methods of using the small molecule ligand-drug conjugates for targeted treatment of cancer in a patient in need thereof. Further described are methods of sterilizing circulating tumor cells and determining drug concentration in cancer tissue.04-14-2011
20100322854POSITRON EMISSION TOMOGRAPHY IMAGING METHOD - Described herein are compositions and methods for diagnosing and/or monitoring pathogenic disease states using positron emission tomography, wherein the pathogenic cells uniquely express, preferentially express, or overexpress vitamin receptors. Also described herein are 12-23-2010
20110097263KIT FORMULATION FOR THE PREPARATION OF IMMUNOLIPOSOME DRUG IN COMBINED BIMODALITY RADIOCHEMOTHERAPY - A kit formulation for the preparation of immunoliposome drug in combined chemotherapy and radionuclide therapy is disclosed, which consists: (1) a vial A containing proteins; (2) a vial B containing Traut's reagent; (3) a vial C containing DSPC, Cholesterol, mPEG-DSPE, Mal-DSPE-PEG and chemotherapy drug; (4) a vial D containing BMEDA, gluconate acetate, SnCl04-28-2011
20100028257PHARMACEUTICAL COMPOUNDS - Nonane and decane diazabicyclic derivatives having homopiperazine as main ring, having affinity for the opioidergic μ and/or δ and/or k receptors and/or for all their receptorial subclasses, with central and/or peripheral activity, having formula (I), the isomeric forms and their mixtures included, wherein one or more atoms are in the corresponding isotopic forms:02-04-2010
20100297007LIGAND DIRECTED TOROIDAL NANOPARTICLES FOR THERAPY AND DIAGNOSTIC IMAGING - The present invention provides nanoparticles, methods of making the nanoparticles, and methods of using the nanoparticles to deliver therapeutic agents and/or imaging agents.11-25-2010
20100278731Mechanism-Based Targeted Pancreatic Beta Cell Imaging and Therapy - Compositions for imaging pancreatic beta cells comprise chelator-antidiabetic agent conjugates and optionally chelated metals.11-04-2010
20110305632PROCESS FOR THE PREPARATION OF ASYMMETRICAL BIS(THIOSEMICARBAZONES) - The present invention relates to a method of making asymmetrical bis(thiosemicarbazones), compounds useful as synthetic intermediates in the method, new bis(thiosemicarbazones) that can be readily accessed by use of the method and methods of treatment and imaging utilising some of the new bis(thiosemicarbazones).12-15-2011
20090274622NECROSIS AVID TRACER AGENT - The invention relates to a method for obtaining an image of ischemic, infarcted or necrotic tissue in a subject, comprising the step of administering an imaging agent comprising a phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound. For example, the invention concerns to the use of phenanthro[1,10,9,8-opqra]perylene-7,14-dione derivatives, and more specifically hypericin or its derivatives, as necrosis or infarct specific agents. The phenanthro[1,10,9,8-opqra]perylene-7,14-dione derivatives can be labeled with a radionuclide, a radiopaque material or a material enhancing the effects magnetic resonance imaging. The invention further features a pharmaceutical composition comprising a phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound optionally conjugated to a radionuclide or a radiopaque material, provided that said phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound is not mono-[11-05-2009
20100322855Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using - Substituted 1,4,7-triazacyclononane-N,N′,N″-triacetic acid and 1,4,7,10-tetraazacyclcododecane-N,N′,N″,N′″-tetraacetic acid compounds with a pendant amino or hydroxyl group, metal complexes thereof, compositions thereof, and methods of making and use in diagnostic imaging and treatment of cellular disorders.12-23-2010
20090297443Labeled ALPHA4BETA2 Ligands and Methods Therefor - Contemplated compositions and methods are employed to bind in vitro and in vivo to an α4β2 nicotinic acetylcholine receptor in a highly selective manner. Where such compounds are labeled, compositions and methods employing such compounds can be used for PET and SPECT analysis. Alternatively, and/or additionally contemplated compounds can be used as antagonists, partial agonists or agonists in the treatment of diseases or conditions associated with α4ββ2 dysfunction.12-03-2009
20110064656Methods of Determining Renal Function using Technetium-99m Tricarbonyl-nitrilotriacetic acid - This disclosure relates to the methods of imaging the kidneys and measuring renal function using the renal tracer 03-17-2011
20110318266PHTHALIMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS - Disclosed are mGluR4 positive allosteric modulator ligands of general formula (I) and radiolabeled derivates, their use as therapeutic agents for the treatment of central nervous system disorders modulated by mGluR4 and as ligands for the labeling and diagnostic imaging of mGluR4 in mammals.12-29-2011
20120003151METHOD FOR EARLY IMAGING OF ATHEROSCLEROSIS - The invention relates to methods of detecting active atherosclerotic plaques associated with blood vessel walls wherein the plaques comprise activated macrophages having accessible binding sites for a ligand. In one embodiment, plaques that block from about 2% to about 60% of the lumen of a blood vessel can be detected.01-05-2012
20120207674CANCER-IMAGING AGENT AND METHOD OF RADIOIMAGING USING THE SAME - The cancer-imaging agent and method of radioimaging relates to the use of a radioimaging agent for the imaging increased choline uptake to detect cancerous tissue. The radioimaging agent includes choline or a pharmaceutically acceptable salt thereof labeled with technetium-99m. Preferably, the radioimaging agent is [methyl]-choline chloride labeled with 08-16-2012
20120128586METHOD FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA - The present invention provides a method for treating a subject having chronic lymphocytic leukemia (CLL) comprising administering to the subject one or more agents that target cell surface membrane antigens expressed preferentially on cells of the proliferative compartment of a CLL clone of the subject to treat chronic lymphocytic leukemia in the subject. The present invention also provides a method for treating a subject having chronic lymphocytic leukemia comprising administering to the subject one or more agents that target cell surface membrane antigens expressed preferentially on cells of the “resting re-entry compartment” to treat chronic lymphocytic leukemia in the subject.05-24-2012
20090202436Bupivacaine Formulation in a Polyorthoester Carrier - Effective treatments of pain, such as chronic pelvic pain, for extended periods of time are provided. The treatments include the administration of one or more drug depots intraspinally wherein the drug depots include an effective amount of bupivacaine formulated within a polyorthoester. By administration of one or more drug depots, one can relieve pain caused by diverse sources, including but not limited to chronic pelvic pain syndromes, spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. In some embodiments, the relief can be for at least thirty days, at least sixty days, at least one hundred days or at least one hundred and thirty-five days.08-13-2009
20110104054Small-Molecule HSP90 Inhibitors - Hsp90 inhibitors having are provided having the formula:05-05-2011
20110104056NOVEL MOLECULAR ASSEMBLY, MOLECULAR PROBE FOR MOLECULAR IMAGING AND MOLECULAR PROBE FOR DRUG DELIVERY SYSTEM USING THE SAME, AND MOLECULAR IMAGING SYSTEM AND DRUG DELIVERY SYSTEM - The present invention provides a molecular assembly which is less likely to accumulate in tissue other than cancer tissue, is highly safe for a living body, and can be prepared by a simple and safe method and whose particle size can be easily controlled. The present invention provides a molecular imaging system and a molecular probe useful for the system, and a drug delivery system and a molecular probe useful for the system. The present invention provides a method for preparing molecular assembly, by which the particle size of molecular assembly having a signal group or a drug can be arbitrarily controlled in order to allow the molecular assembly to effectively accumulate in cancer tissue by utilizing EPR effect. A molecular assembly comprising: an amphiphilic block polymer A comprising a hydrophilic block chain and a hydrophobic block chain having 10 or more lactic acid units; a hydrophobic polymer A2 having at least 10 or more lactic acid units; and/or a labeled polymer B comprising at least 10 or more lactic acid units and a labeling group.05-05-2011
20120219496GADOLINIUM-LINKED NANOCLUSTERS - The invention relates to nanocluster compositions and uses thereof. Specifically, the invention relates to gadolinium-linked nanocluster compositions and their use in diagnosis and prognosis of diseases. The nanocluster compositions of the invention are effective in enhancing the payload of a gadolinium and thereby increasing the longitudinal relaxivity of each particle in the cluster.08-30-2012
20100092385Novel Heteroaryl Substituted Imidazo [1,2-A] Pyridine Derivatives - The present invention relates to novel heteroaryl substituted imidazopyridine derivatives, precursors thereof, and therapeutic uses of such compounds, having the structural formula (Ia) and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel heteroaryl substituted imidazopyridine derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents.04-15-2010
20120128585Method of Diagnosing the presence of a tumor in a mammal by assessing CDO expression level - The present invention provides for a method of using BOC/CDO hedgehog antagonists to inhibit hedgehog signaling, as well as treating and diagnosing disorders relating to hedgehog signaling or overexpression of hedgehog, including cancer, cell proliferative disorders, and angiogenesis, neurological disorders, as well as other conditions affected by hedgehog signaling such as hair growth, neural stem cell differentiation, chondrogenesis and osteogenesis, lung surfactant production, formation of lamellated bodies in lung cells.05-24-2012
20100021380DIEGHYLENETRIAMINEPENTAACETIC ACID (DTPA)-MODIFIED FERROFLUID, PREPARATION METHOD OF THE SAME AND USES OF THE SAME IN PREPARATION OF PEPTIDE FERROFLUID - A present invention relate to a diethylenetriaminepentaacetic acid (DTPA)-modified ferrofluid and a preparation method of the same. The DTPA-ferrofluid contains DTPA and a nano ferrofluid. The DTPA-ferrofluid can be further mixed with a peptide. Unmodified or modified peptide ferrofluids prepared from the DTPA-modified ferrofluid, such as unmodified or modified octreotide-containing or unmodified or modified lanreotide-containing ferrofluid.01-28-2010
20080219921Novel Technetium and Rhenium Complexes. - Novel radioactive technetium and rhenium complexes comprising tripodal ligands are provided by the present invention. In particular, Tc(I) complexes are provided by the present invention. Novel ligands suitable for the formation of the technetium and rhenium complexes of the invention are also provided, as well as radiopharmaceutical compositions comprising said complexes, kits for their preparation. The invention also relates to the us of 09-11-2008
20120219497RANDOM ETHYLENE OXIDE AND NON-RANDOM ALKYLENE OXIDE(S) POLYMERS - A polymeric material comprised of (i) at least one random copolymer comprised of ethylene oxide and one or more other alkylene oxide(s) and (ii) at least one non-random polymer comprised of one or more poly(alkylene oxide)s has been discovered. Preferably, it is a polymer alloy. Alkylene oxide homo-polymers or block copolymers may be the non-random polymer. In a related discovery, an adhesive material can be made by suspending (a) particles in (b) a matrix of at least one poly(ethylene oxide) copolymer of ethylene oxide and propylene oxide, or a combination thereof. The handling characteristics may be adjusted for different utilities (e.g., from runny oil to hard wax). Applications include use as adhesive, cohesive, filler, lubricant, surfactant, or any combination thereof. In particular, the hard materials may be used for cleaning or waxing.08-30-2012
20100172834METHOD FOR AUTOMATED, LARGE-SCALE MEASUREMENT OF THE MOLECULAR FLUX RATES OF THE PROTEOME OR THE ORGANEOME USING MASS SPECTROMETRY - Disclosed here is a method for measuring the kinetics (i.e., the molecular flux rates—synthesis and breakdown or removal rates) of a plurality of proteins or organic metabolites inn living systems. The methods may be accomplished in a high-throughput, large-scale automated manner, by using existing mass spectrometric profiling techniques and art well known in the fields of static proteomics and static organeomics, without the need for additional biochemical preparative steps or analytic/instrumental devices.07-08-2010
20120171116Arginase Inhibitors and Methods of Use Thereof - The present invention includes arginase enzyme inhibitors, compositions comprising these arginase inhibitors, and methods of treating or diagnosing conditions characterized either by abnormally high arginase activity or abnormally low nitric oxide levels in a mammal, comprising administering compositions of the invention to the mammal.07-05-2012
20120251443IMPLANTABLE CONTRAST AGENTS AND METHODS - The present disclosure provides compositions and methods based on implantable contrast agents that are useful for imaging tissue and organs.10-04-2012
20100247433Use of non-canonical amino acids as metabolic markers for rapidly-dividing cells - The invention provides methods, reagents and systems to preferentially mark fast-proliferating cells/tissues (such as cancer), by incorporating non-natural amino acids into proteins, preferably in vivo, using the endogenous protein synthesis machinery of an organism. The incorporated non-natural amino acids contain reactive groups for further chemical reagents, which may serve as a “handle” to for a number of uses, such as imaging of cancer cells, targeting drugs to preferentially kill cancer cells, and proteomic analysis in the context of large scale or high throughput screening for candidate drug leads that affects the proliferation of a target cell, etc.09-30-2010
20120177569LABELLED BIOTIN CONJUGATES - The present invention provides radioactive gallium complexes which comprise DOTA-biotin conjugates, incorporating a linker group. Also described are radiopharmaceutical compositions, and methods and uses of the complexes for in vivo imaging involving pre-targeting with avidin.07-12-2012
20120177570TRPV1 ANTAGONISTS INCLUDING AMIDE SUBSTITUENT AND USES THEREOF - The invention relates to compounds of formula IA″07-12-2012
20100272642PET PROBE HAVING AN ALKOXY GROUP SUBSTITUTED BY FLUORINE AND HYDROXY GROUP - Disclosed are: a PET probe compound having an alkoxy group substituted by a fluorine and a hydroxy group, which is useful for the early diagnosis of a conformational disease; a pharmaceutical composition for the treatment and/or prevention of a conformational disease, which comprises the compound; and others.10-28-2010
20100272641LABELED MOLECULAR IMAGING AGENTS, METHODS OF MAKING AND METHODS OF USE - Imaging agents that comprise labeled substrates of the cystine/glutamate antiporter of cells, whereby the methods of use comprise introducing the labeled agents into cells via the cystine/glutamate antiporter, which are then reduced to a labeled cysteine, and subsequently detected in the cell.10-28-2010
20090060836DERIVATIVES OF 2-NITRO-1,3-IMIDAZOLE COUPLED TO AMINO ACIDS AND DEOXYRIBOSE USEFUL FOR THE DETECTION OF HYPOXIC BIOLOGICAL TISSUE - The present invention relates to a 2-nitroimidazole derivative, a diagnostic pharmaceutical composition which contains such 2-nitroimidazole derivative, the use of the 2-nitroimidazole derivative for the detection of hypoxic biological tissue as well a method for the detection of hypoxic biological tissue by the use of the 2-nitroimidazole derivative.03-05-2009
20100278730Non-Invasive Molecular Imaging of Cellular Histone Deacetylase Substrate Using Magnetic Resonance Spectroscopy (MRS) or Positron Emission Tomography (PET) - We disclose methods of detecting histone deacetylase activity in a mammal by administering to the mammal a compound comprising at least one atom having a nucleus detectable by magnetic resonance spectroscopy, wherein the compound is a substrate of histone deacetylase; and observing the compound or a cleavage product thereof in at least a portion of the body of the mammal by magnetic resonance spectroscopy (MRS). We also disclose methods of detecting histone deacetylase activity in a mammal by administering to the mammal a compound comprising at least one positron-emission-decaying radioisotope, wherein the compound is a substrate of histone deacetylase; and observing the compound or a cleavage product thereof in at least a portion of the body of the mammal by positron emission tomography (PET). We also disclose compounds useful as histone deacetylase substrates.11-04-2010
20110123446DEGRADABLE COMPOUNDS AND METHODS OF USE THEREOF, PARTICULARLY WITH PARTICLE REPLICATION IN NON-WETTING TEMPLATES - The present invention provides compounds that will degrade under specified conditions, methods of using such compounds, and compositions comprising such compounds. The degradable compounds of the invention may be characterized by the labile —Si-A-C— groups present in the compounds (A representing an atom, such as O, N, or S, or a group, such as C═O). The compounds may be incorporated into a composition that further may include a polymeric matrix and/or a cargo component. A wide variety of cargo components may also be used in the present invention. In particular embodiments, the cargo component comprises a drug or other therapeutic agent. Accordingly, the invention particularly provides pharmaceutical formulations and methods of delivering a drug or other therapeutic material.05-26-2011
20110038793MICROSPHERE COMPRISING AN ORGANIC LANTHANIDE METAL COMPLEX - The invention provides a microsphere comprising an organic lanthanide metal complex wherein the lanthanide metal is present in an amount of more than 20 wt %, based on total microsphere. The invention further provides a suspension comprising such a microsphere. In addition, the invention relates to a method for preparing said microsphere, and the use of the microsphere(s) or suspension for treating a malignancy and/or obtaining a scanning image.02-17-2011
20080299038Luminescent Metal Complexes for Monitoring Renal Function - Some embodiments of the present invention may be said to be directed to metal complexes of Formula I, wherein at least one of X12-04-2008
20110002847METHOD OF FORMING AN INJECTABLE RADIOACTIVE COMPOSITION OF A CARBON ENCAPSULATED RADIOACTIVE PARTICULATE - A method of forming an injectable radioactive composition, the method comprising the steps of: (a) depositing a solid form of technetium onto a carbon crucible; (b) preheating the solid form of technetium to remove any carrier; (c) plasma ablating the technetium and portions of the carbon crucible; (d) allowing the carbon and technetium metal to co-condense from the gas phase to produce a nanoparticle composite aerosol in an inert gas; (e) dispersing the nanoparticle composite in water containing a low concentration of surfactant using an electrostatic precipitator; (f) size fractionating the nanoparticle dispersion by filtration with hydrophilic membranes of known pore size.01-06-2011
20110236308Aryl Bidentate Isonitriles and Their Uses - The present invention relates generally to chelation compounds, radionuclide metal chelate compounds, i.e., complexes, and radiolabeled targeting moieties, i.e., conjugates, formed therefrom, and methods of using these compounds, complexes and conjugates for diagnostic and therapeutic purposes. This invention is more particularly related to aryl bidentate isonitrile metal complexes generated by a chemical interaction of a metal salt oxide or weak complex of the metal with aryl isonitrile bidentate ligands.09-29-2011
20120321559HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS - Certain hexahydro-pyrrolo-isoquinoline compounds are histamine H12-20-2012
20120321558COMPOSITIONS OF HIGH SPECIFIC ACTIVITY SN-117M AND METHODS OF PREPARING THE SAME - Compositions of high specific activity 12-20-2012
20120328514N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS - The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.12-27-2012
20100215574PROCESS FOR PRODUCING AN INJECTABLE MEDICAMENT PREPARATION - The invention relates to a method for producing injectable medicament preparations containing a therapeutically and/or diagnostically effective substance which is comprised of an active agent, of a spacer molecule and of at least one protein-binding molecule. After being brought into contact with the body, said therapeutically and/or diagnostically effective substance covalently bonds to the body fluid constituents or tissue constituents via the protein-binding molecule, thus providing a form of transport of the active agent that an be hydrolytically or enzymatically cleaved, according to pH, in the body while releasing the active agent.08-26-2010
20130017149PHARMACEUTICAL COMPOUNDS - Condensed tricyclic compounds having a condensed structure containing one phenyl and one pyrazole ring linked with each other by a central ring comprising from five to eight atoms, having affinity for the CB1 and/or CB2 receptors, with central nervous system and/or peripheral activity, of formula (I):01-17-2013
20090324495COMPOUNDS AND METHODS FOR ENZYME-MEDIATED TUMOR IMAGING AND THERAPY - The invention provides methods and compositions, e.g., for tumor imaging and therapy.12-31-2009
20130171067TECHNETIUM-99m COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS - The invention relates to a compound having formula (I), compositions containing same and preparation methods thereof. The invention also relates to a complex of the compound having formula (I) with technetium-99m and tricine, the use of this complex as a diagnostic probe, diagnostic compositions containing same and methods for preparing the complex and compositions containing same.07-04-2013
20080226550SMALL TECHNETIUM-99M AND RHENIUM LABELED AGENTS AND METHODS FOR IMAGING TUMORS - The present invention relates to compounds and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic treatment of tumors, e.g., carcinomas, melanomas and other tumors. In another embodiment, the invention relates to methods of imaging tumors using radiolabeled metal complexes. Preferred radiolabeled complexes for imaging tumors include technetium and rhenium complexes. The high tumor uptake and significant tumor/nontumor ratios of the technetium complexes of the invention indicate that such small technetium-99m-based molecular probes can be developed as in-vivo diagnostic agents for melanoma and its metastases. In yet another embodiment, the invention relates to methods of treatment of tumors using a radiolabeled metal complex as a radiopharmaceutical agent to treat the tumor.09-18-2008
20110262351FLUORESCENT SILICA NANOPARTICLE WITH RADIOACTIVE TAG AND THE DETECTING METHOD OF PET AND FLUORESCENT DUAL IMAGING USING THEREOF - The present invention relates to nuclear medicine using fluorescent silica nanoparticle and detecting method of optical dual imaging, and more particularly to radioisotope labeled fluorescent silica nanoparticles which are used for PET (positron emission tomography) and fluorescence detecting, and detecting method of PET and fluorescent dual imaging using thereof. Functionalized silica nanoparticles of this invention have promising potential as a role for organic lymphatic tracer in biomedical imaging such as pre- and intra-operative surgical guidance.10-27-2011
20130171066POLYMERIC COMPLEMENTS TO A B-AMYLOID PEPTIDES - The present invention relates to the preparation and use of polymer complements to β-amyloid peptides (Aβ) for detecting soluble or aggregated Aβ in fluid samples or for treating a subject having a neurodegenerative disease.07-04-2013
20120093720Molecularly Imprinted Polymers for Use as Imaging and Therapeutics Agents - The invention described herein provides biocompatible molecularly imprinted polymers (MIPs) that are non-toxic, water soluble, small molecular weight, and degradable in a living body. The MIPs are capable of binding to all or a portion of a specific target macromolecule associated with a disease located within the living body and they are derivatized for stealth for in vivo applications to avoid the reticuloendothelial system. The MIPs of the invention are functionalized to an amine or carboxyl group and are derivatized with an imaging and/or therapeutic agent for taking images of the disease and/or for providing therapy. The macromolecule can be selected from a group consisting of proteins, glycoproteins, lipoproteins, peptidoglycans, peptides, polypeptides, polynucleotides, and polysaccharides. The invention described herein also provides methods and kits wherein MIPs of the invention can be employed as targeted imaging and therapeutic agents.04-19-2012
20080219922Alzheimer's Disease Imaging Agents - This invention provides compounds and methods of imaging amyloid deposits using radiolabeled compounds. This invention also provides a method of inhibiting the aggregation of amyloid proteins to form amyloid plaques or deposits, a method of determining a therapeutic compound's ability to inhibit aggregation of amyloid protein, and a method of delivering a therapeutic agent to amyloid deposits.09-11-2008
20130095035POLYANIONIC MULTIVALENT MACROMOLECULES FOR INTRACELLULAR TARGETING OF PROLIFERATION AND PROTEIN SYNTHESIS - The present invention relates generally to methods and compositions for targeting of intracellular molecules involved in proliferation and protein synthesis of activated cells using polyanionic multivalent macromolecules. In particular aspect, multiple sulfate groups linked to polyol are specifically targeted to the cytoplasm and nucleus of proliferating and activated cells. The invention further comprises novel polyanionic macromolecular compounds and formulations.04-18-2013
20130101505Stable Activatable Particles as Radiotherapeutic Agents for the Treatment of Disease - The present invention provides radiotherapeutic agents and compositions and methods for making and using the same. In some embodiments, the radiotherapeutic agent is a nanoparticle comprising a radionuclide and a carrier moiety. In some embodiments, the radionuclide is produced by activating a stable activatable particle via neutron activation.04-25-2013
20130129620Tricarbonyl Complexes with Tridentate Chelators for Myocardium Imaging - Chelators of the formulae (I), (II) and (III)05-23-2013
20100284913Methods and compositions for studying, imaging, and treating pain - Saxitoxin analogue compounds, compositions, pharmaceutical compositions, methods of synthesis of saxitoxin analogues, methods of imaging, methods of treatment, including methods of treating pain, are provided. Saxitoxin (STX), gonyautoxin (GTX), and zetekitoxin, and variant STX compounds bind to sodium channels and are effective to reduce or block flow of sodium ions through such channels. Such channel block affects nerve and muscle action, and may be effective to reduce or block pain sensations, relax muscles, reduce muscle spasm, and reduce wrinkles. STX analogue binding to sodium channels may also be useful to locate, image, or mark sodium channels, and so be useful in studying sodium channels and sodium channel disorders, and in the diagnosis and treatment of patients suffering from sodium channel disorders. In embodiments, the variant STX compounds include conjugates having increased serum half-life as compared to STX when administered to a subject.11-11-2010
20100316566RADIOLABELED HEDGEHOG DERIVATIVES FOR IMAGING AND THERAPY - The present invention concerns methods and compositions related to a chelator and a HHRT ligand. In specific embodiments of the invention the chelator is conjugated to the HHRT ligand. In another specific embodiment of the invention, the chelator is chelated to a metal. In a particular embodiment of the invention, there is a metal species that is chelated to a chelator, which is then directly or indirectly conjugated to a HHRT ligand. In some embodiments, the composition further comprises a therapeutic agent. In particular cases, the compositions are employed for cancer diagnosis and/or therapy.12-16-2010
20130183236MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS - The present invention provides targeted delivery compositions and methods of using the compositions for treating and diagnosing a disease state in a subject.07-18-2013
20110286919CONJUGATES OF NOSCAPINE AND FOLIC ACID AND THEIR USE IN TREATING CANCER - The present invention is directed to compounds which are conjugates of two non-toxic natural products, noscapine (and various noscapine analogs) and folic acid (and various folic acid analogs), where the folic acid is conjugated to noscapine or the noscapine analog at the 9-position on the isoquinoline ring on the noscapine framework. Pharmaceutical compositions including the compounds, and methods of treating various tumors using the compounds and compositions, are also disclosed. The conjugates are particularly useful for treating cancers which overexpress the Folate Receptor α (FRa) receptor.11-24-2011
20110311444IMAGING DIAGNOSTIC AGENT AND EXTRACORPOREAL DIAGNOSTIC AGENT FOR INCURABLE NEUROLOGICAL DISEASES - Disclosed are a curcumin derivative or a salt thereof, which contains a fluorine atom, represented by formula (I):12-22-2011
20130189185Boron-Based Dual Imaging Probes, Compositions and Methods for Rapid Aqueous F-18 Labeling, and Imaging Methods Using Same - A composition useful as a PET and/or fluorescence imaging probe a compound a compound of Formula I, including salts, hydrates and solvates thereof:07-25-2013
20130202529BENZTROPINE COMPOUNDS AND USES THEREOF - Disclosed are benztropine analogs having the formula (I)08-08-2013
20120070372NON-INVASIVE DIAGNOSTIC AGENTS OF CANCER AND METHODS OF DIAGNOSING CANCER, ESPECIALLY LEUKEMIA AND LYMPHOMA - The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.03-22-2012
20130209357MOLECULAR PROBES FOR IMAGING MYELIN - A molecular probe for use in the detection of myelin in a subject includes a compound having the general formula selected from the group consisting of: formula (I), and pharmaceutically acceptable salts thereof.08-15-2013

Patent applications in class In an organic compound

Patent applications in all subclasses In an organic compound